Arbutus Biopharma's worrying high P/S ratio is underscored by its falling revenue. Investors could pay a steep premium as these declines might significantly affect the stock's value.
The Court of Appeals for the Federal Circuit (CAFC) just issued it's Mandate in connection with$モデルナ(MRNA.US)$'s unsuccessful appeal of the '069 patent's validity. So the CAFC is now done with the case. Good news for$アービュタス バイオ ファーマ(ABUS.US)$.
$モデルナ(MRNA.US)$'s deadline for filing a petition for rehearing at the Federal Circuit for the '069 patent case (no. 20-2329) passed last night, without any filing by MRNA. This is good for$アービュタス バイオ ファーマ(ABUS.US)$and $ROLV
3
2
報告
Perfume_girl :
Please, can you explain "why" is it good for $ABUS and $ROIV ?
Shaaawスレ主Perfume_girl:
It exhausts the $mrna appeal to invalidate the $abus patents in question. If they so choose, Genevant will proceed with an infringement suit, if the parties are not negotiating already?
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long